Gefitinib in Non Small Cell Lung Cancer

Gefitinib in Non Small Cell Lung Cancer

Gefitinib is an oral, reversible, tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) that plays a key role in the biology of non small cell lung cancer (NSCLC). Phase I studies indicated that the recommended dose of gefitinib was 250 mg/day. Rash, diarrhea, and nausea were the most...

Full description

Bibliographic Details
Main Authors: Raffaele Costanzo, Maria Carmela Piccirillo, Claudia Sandomenico, Guido Carillio, Agnese Montanino, Gennaro Daniele, Pasqualina Giordano, Jane Bryce, Gianfranco De Feo, Massimo Di Maio, Gaetano Rocco, Nicola Normanno, Francesco Perrone, Alessandro Morabito
Format: Article
Language:English
Published: Hindawi Limited 2011-01-01
Series:Journal of Biomedicine and Biotechnology
Online Access:http://dx.doi.org/10.1155/2011/815269

Internet

http://dx.doi.org/10.1155/2011/815269

Similar Items